Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 13.3% in November

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 25,500 shares, a drop of 13.3% from the October 31st total of 29,400 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 41,600 shares, the days-to-cover ratio is currently 0.6 days.

Daré Bioscience Price Performance

DARE stock traded down $0.02 during trading on Tuesday, hitting $3.28. The company had a trading volume of 52,295 shares, compared to its average volume of 46,893. The company has a fifty day moving average price of $3.55 and a two-hundred day moving average price of $3.87. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $7.56.

Analyst Upgrades and Downgrades

DARE has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a report on Friday, November 15th. Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.